Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis

Lumacaftor/ivacaftor (LUMA-IVA) therapy is prescribed to people with cystic fibrosis (pwCF) homozygous for the Phe508del-CFTR variant to restore CFTR protein function. There is, however, large inter-individual variability in treatment response. Here, we seek to identify clinical and/or genetic facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Mésinèle, Julie, Ruffin, Manon, Guillot, Loïc, Boëlle, Pierre-Yves, Corvol, Harriet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876860/
https://www.ncbi.nlm.nih.gov/pubmed/35207740
http://dx.doi.org/10.3390/jpm12020252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876860/
https://www.ncbi.nlm.nih.gov/pubmed/35207740
http://dx.doi.org/10.3390/jpm12020252

Ejemplares similares